Omega Therapeutics IPO Presentation Deck
Investment Highlights
Investment Highlights
Programmable
mRNA medicines
delivered via LNPS
Ⓒ2021 Omega Therapeutics, Inc.
Novel DNA-
sequence-based
epigenomic
targets enabling
precision gene
tuning
Leading program in
CMYC as only the
first;
8 high-value
development
programs
A
What We Have Achieved To Date
Programmable mRNA-encoded OECs with high
specificity, tunability and durability
Proprietary database of thousands of novel
EpiZip targets, across the ~15,000 IGDs
Initiated 8 programs using our Epigenomic
Controllers; over 100 more discovery targets
Raised over $200M; 15 leading investor partners
Assembled a world class team
Omega aims to be a leader in genomic medicines
by selectively controlling the human genome to treat and cure serious diseasesView entire presentation